Business Description
Aldeyra Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US01438T1060
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 9.12 | |||||
Equity-to-Asset | 0.81 | |||||
Debt-to-Equity | 0.13 | |||||
Debt-to-EBITDA | -0.45 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 17.5 | |||||
3-Year EPS without NRI Growth Rate | 15.5 | |||||
3-Year FCF Growth Rate | 22.5 | |||||
3-Year Book Growth Rate | 9.6 |
Momentum Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 48.34 | |||||
9-Day RSI | 50.53 | |||||
14-Day RSI | 52.38 | |||||
6-1 Month Momentum % | 119.13 | |||||
12-1 Month Momentum % | -63.52 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 6.64 | |||||
Quick Ratio | 6.64 | |||||
Cash Ratio | 6.42 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -15.3 | |||||
Shareholder Yield % | -0.03 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -28.4 | |||||
ROA % | -23.44 | |||||
ROIC % | -345.67 | |||||
ROC (Joel Greenblatt) % | -14816.62 | |||||
ROCE % | -24.98 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 2 | |||||
Price-to-Tangible-Book | 1.93 | |||||
EV-to-EBIT | -3.01 | |||||
EV-to-Forward-EBIT | -1.79 | |||||
EV-to-EBITDA | -3.03 | |||||
EV-to-Forward-Revenue | 11.49 | |||||
EV-to-FCF | -3.74 | |||||
Price-to-Net-Current-Asset-Value | 1.94 | |||||
Price-to-Net-Cash | 2.03 | |||||
Earnings Yield (Greenblatt) % | -33.19 | |||||
FCF Yield % | -12.96 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Aldeyra Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -0.594 | ||
Beta | 0.84 | ||
Volatility % | 124.58 | ||
14-Day RSI | 52.38 | ||
14-Day ATR (€) | 0.177475 | ||
20-Day SMA (€) | 3.84635 | ||
12-1 Month Momentum % | -63.52 | ||
52-Week Range (€) | 1.375 - 11.01 | ||
Shares Outstanding (Mil) | 59.41 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Aldeyra Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Aldeyra Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Aldeyra Therapeutics Inc Frequently Asked Questions
What is Aldeyra Therapeutics Inc(STU:137)'s stock price today?
When is next earnings date of Aldeyra Therapeutics Inc(STU:137)?
Does Aldeyra Therapeutics Inc(STU:137) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |